Project Grant R01CA295997
Award Date
12/2/24
Completion Date
11/30/29
Dollars Obligated
$552K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
This Project Grant award of $219,491 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research by Mayo Clinic Jacksonville to study the role of the ECT2 gene isoform switch in pancreatic ductal adenocarcinoma (PDAC). The research aims to determine the status of the ECT2-EX4+ isoform in PDAC precursor lesions and tumors, define its specific role in normal pancreas cells and PDAC tumor growth/metastasis, and examine how ECT2 exon 4 impacts...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The University of Texas Southwestern Medical Center (UT Southwestern) supports research into mechanisms of therapeutic resistance in cancer. The $449,196 award, which runs from April 1, 2025 to March 31, 2030, focuses on investigating how receptor tyrosine kinase (RTK) inhibition triggers rapid sumoylation of RTKs, leading to adaptative responses that drive secondary resistance to targeted...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $546,349 to The University of Texas Southwestern Medical Center to investigate the molecular mechanisms by which the Von Hippel-Lindau (VHL) tumor suppressor regulates gene expression via N6-methyladenosine (m6A) modification in clear cell renal cell carcinoma (ccRCC). The research aims to determine how VHL interacts with the m6A enzymatic complex to control m6A-dependent gene expression,...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to the University of Texas MD Anderson Cancer Center to conduct research aimed at understanding how mutations in the TP53 tumor suppressor gene drive pro-metastatic interactions between pancreatic cancer cells and the surrounding tumor microenvironment. The $453,304 award will fund a 5-year project focused on clarifying the signaling mechanisms by which mutant TP53 activates the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The University of Texas Southwestern Medical Center provides $472,458 to conduct research aimed at overcoming mechanisms of PTPN1 driving therapy- and castration-resistant prostate cancer. The 5-year project, starting December 1, 2024, will investigate the regulation of the PTPN1 gene and its role in the transition of prostate cancer cells to a therapy-resistant neuroendocrine...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), provides $698,008 to The Trustees of the University of Pennsylvania to conduct research on the regulation of histone propionylation in pancreatic ductal adenocarcinoma (PDA). The project aims to elucidate the mechanism by which branched-chain amino acid metabolism generates nuclear propionyl-CoA to modulate histone propionylation and gene expression, with the goal...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) is supporting research at the University of Pennsylvania to investigate the role of the epigenetic regulator ENL in kidney development and Wilms tumor formation. The $541,647 award, effective May 1, 2025 through April 30, 2030, will enable researchers to develop innovative mouse models and use patient-derived organoids, single-cell transcriptomics/epigenomics, and small-molecule inhibitors to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $112,052 to The Trustees of the University of Pennsylvania to conduct research aimed at overcoming treatment resistance in gynecological cancers. The key products and services to be delivered include: Testing new therapies that exploit survival pathways critical for cancers with CCNE1 amplification, which are often platinum-resistant. This includes evaluating biomarkers beyond...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $192,240 to The University of Texas MD Anderson Cancer Center to conduct research on the functional contribution of extracellular vesicles in pancreatic cancer. The research aims to investigate how cancer cell-derived extracellular vesicles modulate the tumor microenvironment to facilitate pancreatic cancer initiation, progression, and metastasis. The goal is to identify novel...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $103,948 to Wayne State University to investigate the role of the Ran guanine exchange factor, RCC1, in pancreatic ductal adenocarcinoma (PDAC) progression. The objectives are to study how RCC1 impacts PDAC metabolic activity and mRNA processing, as well as examine the effects of RCC1 overexpression on PDAC development and metastasis using animal models. The award period runs...